博彩公司排名

个人简介

国家高层次引进人才，中山大学“逸仙学者”，教授，博导；博彩公司排名-博彩公司评级 病原生物学与生物安全系、人类病毒学研究所、热带病防治教育部重点实验室。

研究工作

主要从事黄病毒科病毒（如登革病毒、丙肝病毒、寨卡病毒）的反向遗传、感染、复制和入侵的细胞模型，以及冠状病毒的广谱中和抗体等研究，并利用上述模型研究病毒感染的致病机制、免疫逃逸与耐药等科学问题。关注病毒基因改造相关的生物安全问题。在PNAS, EMBO J, Gastroenterology, Autophagy, EMBO Rep, J Biol Chem, J Virol等重要学术期刊上发表60余篇论文；获多项国家、省级和国际合作项目资助，申请并获得多项专利。

现任J Clin Virol, Virol J, Eur J Med Res, Front Microbiol, Tumor Virus Res和《中国病毒病杂志》杂志编委，Viruses客座编委；曾任《病毒学报》编委。

教育和学习经历

1992-1999年在广西师范大学生物系取得生物学学士和生物化学硕士学位，2000-2004年在中国农业大学生物学院和丹麦皇家兽医研究所完成生物化学与分子生物学博士学位（病毒学方向）。2003-2014年在丹麦技术大学、德国Friedrich-Loeffler动物病毒研究院、加拿大萨斯喀彻温大学传染病和疫苗研究中心（VIDO）、丹麦哥本哈根大学医学院Hvidovre医院传染病学系从事病毒学相关研究，历经博士后、项目研究员、资深研究员等。2014 年1月回国到中山大学。

课题组招聘研究员，副研究员和博士后，欢迎有志从事分子病毒学和抗病毒免疫的青年加入研究组。

Yiping Li (Yi-Ping Li), Ph.D., Professor of Molecular Virology, Institute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University (SYSU), Guangzhou, China.

Dr. Yiping Li’s research interests are primarily in the molecular virology, reverse genetics, antiviral immunity, and drug resistance of the Flaviviridae viruses, such as hepatitis C virus (HCV), dengue virus (DENV), and Zika virus (ZIKV). Additionally, Dr. Li works on the broad neutralizing antibody for coronaviruses. Dr. Li has made important contributions in the development of recombinant chimeras and novel full-length infectious culture systems for HCV genotypes 1-6, infectious clones for DENV-1 to DENV-4, and ZIKV (Asian lineage), and demonstrated novel mechanisms of virus-host interactions and pathogenesis. Dr. Li’s works have led to publications on well-known journals, including PNAS, The EMBO Journal, Gastroenterology, Hepatology, EMBO Reports, Journal of Biological Chemistry, Journal of Virology, Antiviral Research, etc.. Dr. Li have received 5 US and EU patents and filed 9 Chinese patents.

Currently, Dr. Li serves as an Editorial Board member for J Clin Virol, Virol J, Eur J Med Res, Front Microbiol, Tumor Virus Res, and The Chinese Journal of Viral Diseases, as well as a guest editor for Viruses. Previously, he served as the editorial board member for the Chinese Journal of Virology.

Dr. Li received Bachelor and Master in Biochemistry from Guangxi Normal University (Guilin, China) and Ph.D. degree in Biochemistry and Molecular Biology from China Agricultural University (Beijing, China). From 2003 to 2004 and 2006 to 2007, Dr. Li worked as a visiting scholar, project researcher, and postdoctoral researcher in the Royal Veterinary Institute and National Veterinary Institute of Technical University of Denmark, respectively. In 2005, Dr. Li pursued hepatitis C virus (HCV) research in the Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada. To continue HCV research, in February 2008 Dr. Li joined the Copenhagen Hepatitis C Program (CO-HEP), Hvidovre Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, as a senior investigator. In January 2014, Dr. Li took a professor position in Zhongshan School of Medicine, SYSU.

Positions openings and postgraduates: We are recruiting research associates, postdoc, research assistant and trainees. Candidates who pursue their Master and PhD studies are welcome to contact. Please send your cover letter, CV and applications to [email protected]

学术成果

研究论文:

通讯和第一作者论文（*, 通讯作者；#，共同第一作者）       

1. Zhou Q#, Yang Y#, Xu Z, Deng K, Zhang Z, Hao J, Li N, Wang Y, Wang Z, Chen H, Yang Y, Xiao F, Zhang X, Gao S, Li YP*. ATAD1 inhibits hepatitis C virus infection by removing the viral TA-protein NS5B from mitochondria. EMBO Reports. 2023 Nov 6;24(11):e56614. doi: 10.15252/embr.202256614. Epub 2023 Oct 3. (PubMed)
2. He R#, Zheng X#, Zhang J#, Liu B#, Wang Q#, Wu Q, Liu Z, Chang F, Hu Y, Xie T, Liu Y, Chen J, Yang J, Teng S, Lu R, Pan D, Wang Y, Peng L, Huang W, Terzieva V, Liu W*, Wang Y*, Li YP*, Qu X*. SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals. Signal Transduct Target Ther. 2023 Oct 6;8(1):393. doi: 10.1038/s41392-023-01650-x. (PubMed)
3. Hu M#, Li WF#, Wu T, Yang Y, Chen G, Chen T, Liu Y, Mei Y, Wu D, Wei Y, Luo T, Zhang HJ*, Li YP*. Identification of an arylnaphthalene lignan derivative as an inhibitor against dengue virus serotypes 1 to 4 (DENV-1 to -4) using a newly developed DENV-3 infectious clone and replicon. Microbiology Spectrum. 2023 Jun 28:e0042323. doi: 10.1128/spectrum.00423-23. (PubMed)
4. Deng K#, Zhou Q#, Xu Z#, Yang Y, Liu X, Li C, Chen M, Zhang Z, Chen H, Ma L, Anwar MI, Zheng C, Rong L, Huang M, Xia J, Zhou Y, Li YP*. Hepatitis C virus hypervariable region 1 antibodies interrupt E2-SR-B1 interaction to suppress viral infection. iScience. 2023 Mar 16;26(4):106421. doi: 10.1016/j.isci.2023.106421. (PubMed)
5. Peng Y#, Liu Y#, Hu Y#, Chang F, Wu Q, Yang J, Chen J, Teng S, Zhang J, He R, Wei Y, Bostina M, Luo T, Liu W, Qu X*, Li YP*. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses. Frontiers in Immunology. 2022 Dec 22;13:1056272. doi: 10.3389/fimmu.2022.1056272.(PubMed)
6. Chen J#, Yang J#, Chang F#, Hu Y#, Wu Q#, Teng S, Liu Y, Zhang J, He R, Liu B, Zheng X, Liu Z, Peng Y, Xie Z, Zhang Y, Lu R, Pan D, Wang Y, Peng L, Liu W*, Li YP*, Qu X*. Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients. Virologica Sinica. 2023 Jan 19:S1995-820X(23)00005-6. doi: 10.1016/j.virs.2023.01.005. (PubMed)
7. Hao J, Li J, Zhang Z, Yang Y, Zhou Q, Wu T, Chen T, Wu Z, Zhang P, Cui J, Li YP*. NLRC5 restricts dengue virus infection by promoting the autophagic degradation of viral NS3 through E3 ligase CUL2 (cullin 2). Autophagy. 2023 Apr;19(4):1332-1347. doi: 10.1080/15548627.2022.2126614. (PubMed)
8. Hu M, Wu T, Yang Y, Chen T, Hao J, Wei Y, Luo T, Wu D, Li YP*. Development and Characterization of a Genetically Stable Infectious Clone for a Genotype I Isolate of Dengue Virus Serotype 1. Viruses. 2022 Sep 18;14(9):2073. doi: 10.3390/v14092073. (PubMed)
9. Anwar MI, Li N, Zhou Q, Chen M, Hu C, Wu T, Chen H, Li YP*, Zhou Y*. PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication. Virology Journal. 2022 Jul 14;19(1):118. doi: 10.1186/s12985-022-01848-5. (PubMed)
10. Chen M#, Xu Y#, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li YP*. Development of full-length cell culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology, 2021 Dec;102(12). doi: 10.1099/jgv.0.001704. (PubMed)
11. Li J, Zhou Q, Rong L, Rong D, Yang Y, Hao J, Zhang Z, Ma L, Rao G, Zhou Y, Xiao F, Li C, Wang H, Li YP*. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. Antiviral Research. 2021 Jul 9:105136. doi: 10.1016/j.antiviral.2021.105136. (PubMed).
12. Wu T, Wu Z, Li YP*. Dengue fever and dengue virus in the People's Republic of China. Reviews in Medical Virology. 2021 May 19:e2245. doi: 10.1002/rmv.2245. (PubMed)
13. Zheng F, Li N, Xu Y, Zhou Y, Li YP*. Adaptive mutations promote hepatitis C virus assembly by accelerating Core translocation to the endoplasmic reticulum. Journal of Biological Chemistry. 2021 Jan-Jun;296:100018. (PubMed)
14. Zhang J#, Wu Q#, Liu Z#, Wang Q#, Wu J#, Hu Y#, Bai T, Xie T, Huang M, Wu T, Peng D, Huang W, Jin K, Niu L, Guo W, Luo D, Lei D, Wu Z, Li G, Huang R, Lin Y, Xie X, He S, Deng Y, Liu J, Li W, Lu Z, Chen H, Zeng T, Luo Q, Li YP*, Wang Y*, Liu W*, Qu X*. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nature Microbiology. 2021 Jan;6(1):51-58. (PubMed)  
15. Zhou L, Zhou J, Chen T, Chi X, Liu X, Pan S, Chen W, Wu T, Lin T, Zhang X, Li YP*, Yang W*. Identification of Ascomycin against Zika virus infection through screening of natural product library. Antiviral Research. 2021 Dec;196:105210. doi: 10.1016/j.antiviral.20 21.105210. (PubMed)
16. Mishra BK, Yadav UN, Khatiwada S, Tamang MK, Dahal S, Li YP*. Hepatitis C virus genotype and its correlation with viral load in patients from Kathmandu, Nepal. Journal of Infection in Developing Countries. 2020;14(12):1470-1474. (PubMed)
17. Li YP*. Antigen glycosylation broadens the immunogenicity of E2 subunit HCV vaccines. Annals of Blood 2020;5:17 doi: 10.21037/aob-19-77. (Invited Editorial Commentary)
18. Li X, Li J, Feng Y, Cai H, Li YP*, Peng T*. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antiviral Research 2020;177:104734. doi: 10.1016/j.antiviral.2020.104734. (PubMed)
19. Zhang Z, Rong L, Li YP*. Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis. Oxidative Medicine and Cell Longevity 2019 Aug 19;2019:1409582. doi: 10.1155/2019/1409582. PMID: 31531178 (PubMed)
20. Chen M, Zheng F，Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP*. Development of an infectious cell culture system for hepatitis C virus genotype 6a clinical isolate using a novel strategy and its sensitivity to direct-acting antivirals. Frontiers in Microbiology 2018 Dec 4;9:2950. doi:10.3389/fmicb.2018.02950. PMID: 30564209 (PubMed).
21. Zheng Y#, Liu Q#, Wu Y#, Ma L, Zhang Z, Liu T, Jin S, She Y, Li YP*, Cui J*. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. The EMBO Journal 2018;37(18). pii: e99347. PMID: 30065070 (PubMed)
22. Chen Y, Liu T, Zhang Z, Chen M, Rong L, Ma L, Yu B, Wu, Zhang P, Zhu X, Huang X, Zhang H, Li YP*. Novel genetically stable infectious clone for a Zika virus clinical isolate and identification of RNA elements essential for virus production. Virus Research. 2018;257:14-24. PMID: 30144463 (PubMed)
23. Duan X, Anwar MI, Xu Z, Ma L, Yuan G, Chen Y, Liu X, Xia J, Zhou Y, Li YP*. Adaptive Mutation F772S-enhanced p7-NS4A Cooperation Facilitated the Assembly and Release of Hepatitis C Virus and Associated with Enlargement of Lipid Droplets. Emerging Microbes & Infections 2018 Aug 8;7(1):143. PMID: 30087320 (PubMed)
24. Li J, Feng S, Liu X, Guo M, Chen M, Chen Y, Rong L, Xia J, Zhou Y, Zhong J, Li YP*. Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). Virology 2018;518:253-263. PMID: 29549787 (PubMed)
25. Li YP#, Van Pham L#, Uzcategui N, Bukh J. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. Journal of General Virology 2016;97(6):1381-94. PMID:26935756 (PubMed)
26. Li YP#, Ramirez S#, Mikkelsen L, Bukh J*. Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. Journal of Virology 2015;89(1):811-23. PMID: 25355880 (PubMed)
27. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J*. Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors. Gastroenterology 2014;146(3):812-821. PMID:24262279 (PubMed)
28. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J*. Highly efficient full-length hepatitisC virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America 2012;109(48):19757-19762. PMID:23151512 (PubMed)
29. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J*. Robust full-length HCV genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences of the United States of America 2012;109(18):E1101-1110. PMID:22467829 (PubMed)
30. Li YP, Ramirez S, Gottwein JM, Bukh J*. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. Virology 2011;421(2):222-234. PMID:22029937 (PubMed)
31. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J*. MicroRNA-122 antagonism against hepatitis C virus genotype 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5'UTR. Proceedings of the National Academy of Sciences of the United States of America 2011;108(12):4991-4996. PMID:21383155 (PubMed)
32. Li YP*, Vegge CS, Brondsted L, Madsen M, Ingmer H, Bang DD. Campylobacter jejuni induces an anti-inflammatory response in human intestinal epithelial cells through activation of phosphatidylinositol 3-kinase/Akt pathway. Veterinary Microbiology 2011;148(1):75-83. PMID:20863633 (PubMed)
33. Li YP*, Ingmer H, Madsen M, Bang DD. Cytokine responses in primary chicken embryo intestinal cells infected with Campylobacter jejuni strains of human and chicken origin and the expression of bacterial virulence-associated genes. BMC Microbiology 2008;8:107. PMID:18588667 (PubMed)
34. Li YP*, Handberg KJ, Juul-Madsen HR, Zhang MF, Jorgensen PH. Transcriptional profiles of chicken embryo cell cultures following infection with infectious bursal disease virus. Archives of Virology 2007;152(3):463-478. PMID:17143781 (PubMed)
35. Li YP, Handberg KJ*, Kabell S, Kusk M, Zhang MF, Jorgensen PH. Relative quantification and detection of different types of infectious bursal disease virus in bursa of Fabricius and cloacal swabs using real time RT-PCR SYBR green technology. Research in Veterinary Sciences 2007;82(1):126-133. PMID:16678230 (PubMed)
36. Li YP, Kang HN, Babiuk LA, Liu Q*. Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World Journal of Gastroenterology 2006;12(44):7126-7135. PMID:17131474 (PubMed)
37. Li YP, Bang DD, Handberg KJ*, Jorgensen PH, Zhang MF. Evaluation of the suitability of six host genes as internal control in real-time RT-PCR assays in chicken embryo cell cultures infected with infectious bursal disease virus. Veterinary Microbiology 2005;110(3-4):155-165. PMID:16159698 (PubMed)
38. Li YP, Zhang MF*. Rapid pathotyping of Newcastle disease virus from allantoic fluid and organs of experimentally infected chickens using two novel probes. Archives of Virology 2004;149(6):1231-1243. PMID:15168209 (PubMed).

 2、其它贡献作者论文：30余篇（详见PubMed, //pubmed.ncbi.nlm.nih.gov/）

教材专著

1. 译著.Book chapters.

1). 李义平，郑福祥，徐占雪, 病毒感染与人类肿瘤-从基础科学到临床预防（第 九章），ISBN 978-7-03-047942-6，p146-p155，北京:东黄城根北街16号, 科学出版社。（全书三个主译之一）。

2). 李义平，徐占雪，郑福祥，病毒感染与人类肿瘤-从基础科学到临床预防（第10章），ISBN 978-7-03-047942-6，p161-p173，北京:东黄城根北街16号, 科学出版社。（全书三个主译之一）。

2. 特邀专家论坛.综述:

1). 李义平，HCV细胞感染模型研究进展及其在药物研究中的应用，临床肝胆病杂志，2015, 31(11); 1825-1830.

专利

Issued U.S. Patents:

• Li YP, Ramirez S, Gottwein JM, Scheel TKH, and Bukh J, HCV full-length infectious cell culture systems and applications thereof. Patent #: US9382517 B2 (issued date: July 5, 2016).
• Li YP, Ramirez S, Humes D, Gottwein JM, and Bukh J, Novel HCV culture systems and direct-acting antiviral sensitivity. Patent #: US10106783 B2 (issued date: October 23, 2018).
• AlmeidaRS, Li YP, Gottwein JM, and Bukh J, High-titer HCV full-length genotype 2B infectious cell culture systems and applications thereof. Patent #: US10106782 B2 (issued date:     October 23, 2018).
• Bukh J, Li YP, AlmeidaRS, Optimized HCV full-length infectious cell culture systems and applications thereof. Patent #: US10280404 B2 (issued date: May 7, 2019).
• Gottwen JM, Lademann JB, Scheel TKH, Jensen TB, Li YP, Prentoe JC, and Bukh J, Hepatitis C virus expressing reporter tagged NS5A protein. Patent #: 8,772,022 (issued date: July 8, 2014)
• Issued European Patents：
• Li YP, Ramirez S, Gottwein JM, Scheel TKH, and Bukh JHCV full-length infectious cell structure system and applications thereof. EP2828382 (issued date: October 26, 2016).

Filed Patent applications- not yet issued：

Pham VL, Ramirez S, Gottwein J, Li YP, Pedersen J, and Bukh J.Robust Infectious Full-Length HCV Genotype 6a Cell-Culture Models. Denmark 63797DK01,  Application date: February 9, 2018)  

获奖荣誉

基金与奖励

• 2020: 欧盟地平线2020 新冠病毒研究项目（EU Horison 2020, H2020-SC1-PHE-CORONAVIRUS-2020）
• 2020: 国家自然科学基金
• 2020: 国家重研发计划项目"生物安全关键技术"专项
• 2017: 广东省粤港澳科技合作项目
• 2016: 广东省科学技术发展基金
• 2015: 国家自然科学基金
• 2015: 国家重点基础研究发展计划（973计划）
• 2014：广东省自然科学基金
• 2014.01：入选国家高层次引进人才青年项目
• 2014：丹麦Novo Nordisk研究基金 
• 2012-2015：丹麦国家科学技术和创新研究基金-医学科学独立研究基金 
• 2012-2014：丹麦Lundbeck 研究基金 
• 2012：丹麦Novo Nordisk研究基金 
• 2011-2014：丹麦国家科学技术和创新研究基金-医学科学独立研究基金 
• 2006：英国The Houghton Trust基金
• 2003：英国The Houghton Trust基金 

学术兼职

• Journal of Clinical Virology (Editorial borad member)
• Virology Journal
• European Journal of Medical Research
• Tumor Virus Research (Editorial borad member)
• Frontiers in Microbiology (Assodicate editor, Virology section)
• Frontiers in Immunology (Review editor)
• Viruses (Guest editor)
• 中国病毒病杂志
• 病毒学报（2016-2021）
• Danish Society for Virology
• 广东省转化医学学会